Novo Nordisk A/S NOVO-B.CO DK Equity
Novo Nordisk A/S (Nasdaq Copenhagen: NOVO-B.CO) closed at 295.25 DKK, -3.2%, on 2026-08-27, with a trailing P/E of 13.2, a return on equity of 60.7%, a net margin of 33.1% and 3-year sales growth of 20.4%. Institutional ownership, earnings history and filed financials are on the tabs below.
Short interest· FINRA consolidated · settlement 2026-08-14· NVONOVO NORDISK A S
6 settlement cyclesShort interest shown for the US-listed sibling NVO — FINRA covers US listings; figures are that line's shares.
| Shares short | 33.8M |
| % of shares out | — |
| Days to cover | 2.2 |
| Δ vs 2026-07-31 | +15.0% |
bars = shares short · line = days to cover (own scale)
% of shares outstanding suppressed: the listed line's share basis (ADR/depositary) differs from the reported ordinary share count.
FINRA Rule 4560 · twice monthly, published ~a week later.
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.